SCHEMBL22874702

SCHEMBL22874702

CC(C)C1CCN(C(=O)CCC2CCC2)CC1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.59
ALDH1A1 P00352 6/20 0.55
TP53 P04637 1/20 0.54
ATM Q13315 1/20 0.54
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
TPSAB1 Q15661 1/20 0.48
TPSD1 Q9BZJ3 1/20 0.48
TPSG1 Q9NRR2 1/20 0.48
CNR2 P34972 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
GNAI3 P08754 2/20 0.44
GNAO1 P09471 2/20 0.44
GNAI1 P63096 2/20 0.44
CNR1 P21554 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
HIF1A Q16665 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22874700 0.97 HSD11B1 (0.63) HSD11B1ALDH1A1TP53ATMKMT2A
SCHEMBL22874698 0.95 HSD11B1 (0.66) HSD11B1ALDH1A1TP53ATMKMT2A
SCHEMBL26227947 0.95 HSD11B1 (0.66) HSD11B1ALDH1A1TP53ATMKMT2A
SCHEMBL22874701 0.93 HSD11B1 (0.54) HSD11B1ALDH1A1TP53ATMKMT2A
SCHEMBL22875131 0.89 HSD11B1 (0.52) HSD11B1ALDH1A1TP53ATMKMT2A
SCHEMBL26706267 0.84 ALDH1A1 (0.46) HSD11B1ALDH1A1TP53ATMKMT2A
SCHEMBL26747551 0.84 ALDH1A1 (0.46) HSD11B1ALDH1A1TP53ATMKMT2A
SCHEMBL22874789 0.83 TPSAB1 (0.46) HSD11B1ALDH1A1TPSAB1TPSD1TPSG1
SCHEMBL22332287 0.82 GNAI3 (0.43) HSD11B1ALDH1A1TP53ATMTPSAB1
SCHEMBL7919921 0.81 NPC1 (0.48) ALDH1A1KMT2AMEN1GNAI3GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS C4 THERAPEUTICS, INC. (US) 2021-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753397-B2 Cereblon binders for the degradation of ikaros CRBN, IKZF1, IKZF3 HSD11B1 2624/4885ALDH1A1 3363/4885TP53 70/4885
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS CRBN, IKZF1, IKZF3 HSD11B1 3349/4885ALDH1A1 4009/4885TP53 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.